Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer-Reply
JAMA Oncol
.
2020 Dec 1;6(12):1981-1982.
doi: 10.1001/jamaoncol.2020.4821.
Authors
Dae Won Kim
1
,
Michael J Schell
2
,
Richard D Kim
1
Affiliations
1
Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida.
2
Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, Florida.
PMID:
33090188
DOI:
10.1001/jamaoncol.2020.4821
No abstract available
Publication types
Letter
Comment
MeSH terms
Bile Duct Neoplasms*
Biliary Tract Neoplasms* / therapy
Humans
Immunotherapy / adverse effects
Nivolumab
Substances
Nivolumab